New York State Common Retirement Fund Sells 134,406 Shares of TransMedics Group, Inc. $TMDX

New York State Common Retirement Fund decreased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 89.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,240 shares of the company’s stock after selling 134,406 shares during the period. New York State Common Retirement Fund’s holdings in TransMedics Group were worth $1,710,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of TMDX. Marshall Wace LLP lifted its stake in shares of TransMedics Group by 258.7% in the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock valued at $73,275,000 after purchasing an additional 394,340 shares during the period. Zevenbergen Capital Investments LLC increased its holdings in TransMedics Group by 112.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock worth $29,006,000 after purchasing an additional 136,995 shares in the last quarter. Next Century Growth Investors LLC acquired a new position in TransMedics Group in the second quarter valued at approximately $16,049,000. Goldman Sachs Group Inc. lifted its stake in TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after buying an additional 86,721 shares during the period. Finally, First Trust Advisors LP bought a new position in shares of TransMedics Group during the 2nd quarter worth approximately $5,815,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. This trade represents a 17.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director directly owned 12,134 shares in the company, valued at $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 8,920 shares of company stock worth $1,257,310 over the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of research reports. Morgan Stanley boosted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Jefferies Financial Group initiated coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Needham & Company LLC increased their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Finally, Canaccord Genuity Group upped their price target on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Trading Up 4.2%

TMDX opened at $135.06 on Monday. TransMedics Group, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $156.00. The firm has a market capitalization of $4.62 billion, a PE ratio of 54.68 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The company’s 50-day moving average is $133.12 and its 200 day moving average is $124.60.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.